Treventis Corporation is a biotechnology company founded in 2008 and headquartered in Canada. The company is dedicated to treating and preventing protein misfolding diseases using its proprietary Common Conformational Morphology (CCM) discovery engine. This technology enables the identification of druggable active sites in misfolded protein targets, allowing for rational drug design against these targets. Treventis Corporation's lead program focuses on anti-misfolding small molecules in tauopathy, with relevance to Alzheimer’s disease. The company has received a $2.98M grant investment from the Congressionally Directed Medical Research Programs on 18th October 2022. In addition to Alzheimer’s disease, Treventis Corporation is also employing its CCM-driven efforts in oncology and other neurodegenerative diseases, showcasing the wide utility of its technology platform.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $2.98M | 1 |
|
18 Oct 2022 |
| Seed Round | Unknown | 1 | Chiefswood Holdings Limited | 15 Dec 2017 |
| Seed Round | $4.40M | 1 |
|
19 Sep 2013 |
| Seed Round | Unknown | 1 |
|
30 Jul 2012 |
| Seed Round | $550.00K | 1 |
|
06 Mar 2009 |
No recent news or press coverage available for Treventis Corporation.
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
